TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

miR-150 inhibits proliferation and tumorigenicity via retarding G1/S phase transition in nasopharyngeal carcinoma

(2017) Xiangyong Li et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway

(2017) Dong Ren et al.   Molecular Cancer

Phospholipid Phosphatase 4 promotes proliferation and tumorigenesis, and activates Ca2+-permeable Cationic Channel in lung carcinoma cells

(2017) Xin Zhang et al.   Molecular Cancer

Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway

(2017) Dong Ren et al.   Oncotarget

EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib

(2016) J. P. De Andrade et al.   MOLECULAR CANCER THERAPEUTICS

TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation

(2016) J Kang et al.   ONCOGENE

Transcription factor AP-2  induces early Cdx2 expression and represses HIPPO signaling to specify the trophectoderm lineage

(2015) Z. Cao et al.   DEVELOPMENT

N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells

(2015) MIN WANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma

(2015) Fakhera Ikram et al.   Molecular Oncology

Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling

(2015) Guanqun Ge et al.   TUMOR BIOLOGY

Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53

(2015) E K Park et al.   Cell Death & Disease

Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway

(2015) Meiyuan Chen et al.   Oncotarget

Sumoylation Pathway Is Required to Maintain the Basal Breast Cancer Subtype

(2014) Maria V. Bogachek et al.   CANCER CELL

Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells

(2014) Dong Ren et al.   CELL AND TISSUE RESEARCH

Inhibition of RHO–ROCK signaling enhances ICM and suppresses TE characteristics through activation of Hippo signaling in the mouse blastocyst

(2014) Kanako Kono et al.   DEVELOPMENTAL BIOLOGY

TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling

(2014) Lingyi Fu et al.   Molecular Cancer

Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

(2013) Y. Touil et al.   CLINICAL CANCER RESEARCH

Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR-145

(2013) DONG REN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145

(2013) Wei Guo et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

BMP4 Administration Induces Differentiation of CD133+Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

(2012) Lixing Zhang et al.   CANCER RESEARCH

A molecular mechanism that links Hippo signalling to the inhibition of Wnt/β-catenin signalling

(2012) Masamichi Imajo et al.   EMBO JOURNAL

TFAP2E–DKK4and Chemoresistance in Colorectal Cancer

(2012) Matthias P.A. Ebert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional Targets Cyr61 and CTGF

(2011) D. Lai et al.   CANCER RESEARCH

microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C

(2011) Elisa Penna et al.   EMBO JOURNAL

The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene

(2011) X Zhang et al.   ONCOGENE

Hippo signaling: growth control and beyond

(2010) G. Halder et al.   DEVELOPMENT

The Hippo Signaling Pathway in Development and Cancer

(2010) Duojia Pan   DEVELOPMENTAL CELL

Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver

(2010) L. Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 Oncogene

(2009) Dawang Zhou et al.   CANCER CELL

AP-2γ promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene

(2009) Christopher M J Williams et al.   EMBO JOURNAL

TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition

(2009) Heng Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Colon cancer stem cells

(2009) Lucia Ricci-Vitiani et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73

(2008) M. Kawahara et al.   BLOOD

Down-regulation of Mammalian Sterile 20-Like Kinase 1 by Heat Shock Protein 70 Mediates Cisplatin Resistance in Prostate Cancer Cells

(2008) A. Ren et al.   CANCER RESEARCH

Mst2 and Lats Kinases Regulate Apoptotic Function of Yes Kinase-associated Protein (YAP)

(2008) Tsutomu Oka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Overexpression ofTFAP2Cin invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival

(2008) JMW Gee et al.   JOURNAL OF PATHOLOGY

TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway

(2008) Q.-Y. Lei et al.   MOLECULAR AND CELLULAR BIOLOGY